University of Oxford emeritus professor Gordon Clark will oversee IP Group's approach to ethical dealmaking and report to the firm's board of directors.

The ultrasound therapeutics developer, a University of Oxford spinout, has raised series B2 funding in the run-up to clinical testing of its cancer drug delivery platform.

Pfizer Ventures joined Mission’s other existing investors to push the mitochondria-focused drug developer’s lifetime funding to approximately $143m.

Colin Steen, one of Syngenta Ventures' managing directors, has departed from the unit after more than two years for a chief executive role elsewhere.

University of Tübingen’s immuno-oncology spinout Immatics has undertaken a reverse merger with special purpose acquisition company Arya Sciences to list in the US.

Maximilian Schausberger has moved to managing director of Raiffeisen's Elevator Ventures unit while Christian Wolf will oversee strategic partnerships and ecosystems for the bank.

The bankrupt satellite internet system developer, which had raised more than $3bn from multiple corporates, has been acquired by a consortium including existing investor Bharti.

Licence agreements at Satt Ouest Valorisation grew year-on-year despite the regional TTO’s patent portfolio shrinking with the disposal of 82 inventions.

Deep tech-focused commercialisation manager Olivia Nicoletti has departed Cambridge Enterprise for a senior role at Angel CoFund.

Todorova, who had spent some three years overseeing Sumitomo's European food and agriculture technology portfolio in Europe, is taking leave.